Du är här

2014-04-28

Medigene AG: Medigene receives new US patent for TCR-modified T cell immunotherapy

Medigene AG / Medigene receives new US patent for TCR-modified T cell
immunotherapy. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 28 April 2014.
The biotech company Medigene AG (Frankfurt: MDG1, Prime Standard) announces
that the US Patent Office has issued patent No. 8,697,854 "High affinity T
cell receptor and use thereof", relating to T-cell receptors against the
tumor associated antigen tyrosinase. The patent has a term until 2030 and is
licensed exclusively to Medigene's wholly owned subsidiary Trianta
Immunotherapies GmbH by Helmholtz Zentrum München.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG
: "We are delighted about this new patent which further extends our patent
portfolio related to our recently acquired TCR-modified T cell
immunotherapy".

About T cell receptor- (TCR) modified T cells
(Late preclinical stage, suited for the treatment of advanced cancer): This
therapy approach of Trianta aims to utilize the body's own machinery - the T
cell - to target and destroy cancer by arming normal patient-derived T cells
with new T cell receptors that enable them to detect and efficiently kill
tumour cells. This form of immunotherapy is supposed to overcome a patient's
tolerance to cancer since the T cells of the patient are activated and
modified outside the body, away from generalized immune suppression in the
patient. Compared to small molecule or antibody based therapies this approach
can be used for new targets to fight tumours. A large army of specific T
cells is made available to patients within just 10 days. Trianta is currently
establishing a comprehensive library of recombinant T-cell receptors and a
GMP-compliant process for their combination with patient-derived T cells.

For Trianta's TCR modified T cells a process for combining these receptors
with autologous T cells in accordance with the regulatory GMP (good
manufacturing practice) standards is being established at present. First
discussions with the regulatory authorities in respect of the preparation of
initial clinical trials with defined product candidates have already taken
place.

About Trianta:
Trianta Immunotherapies GmbH, a wholly owned subsidiary of Medigene AG, is at
the forefront of personalized T cell immunotherapy, focussing on next
generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor
(TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs).
Trianta Immunotherapies was founded late 2013 as a spin-off of the Helmholtz
Zentrum München, the German Research Centre for Environmental Health. Trianta
exploits the therapeutic and commercial potential of T cell-focused therapies
developed by the team of Prof. Dolores J. Schendel at the Helmholtz Zentrum
Munich, in collaboration with Prof. Thomas Blankenstein at the Max Delbrück
Centre for Molecular Medicine, Berlin. The team of Trianta pursues three
complementary immunotherapeutic strategies to target various tumour types and
stages. Each one is focused on T cells, a type of white blood cell that plays
a pivotal role in immunity. Trianta Immunotherapies was acquired by Medigene
in January 2014.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. Medigene concentrates on
the development of personalized T cell immunotherapies with focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, Veregen®, which is distributed by
commercial partners companies. Medigene has various drug candidates in
clinical development and it is developing highly innovative treatment
platforms. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements.
Medigene®EndoTAG®and Veregen®are registered trademarks of Medigene AG.
Polyphenon E®is a trademark of Mitsui Norin Co., Ltd.
These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go
to:http://www.medigene.de/unsubscribe

Press release as PDF
http://hugin.info/132073/R/1780005/608412.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1780005

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.